Considerable strides have been made in the development of cell and gene therapies since the first autologous CAR T therapy was approved by the FDA four years ago.


The breadth of technologies spanning autologous and allogeneic platforms is underpinned by the expansion of receptor/indication targets. Whilst hematological malignancies have formed the bedrock of development, solid tumors are increasingly part of a more complicated arena.

Additionally, regulatory requirements have modified. The assumption that all cell therapies are genetically modified organisms does not universally hold true. Furthermore, the vein-to-vein chain of custody requirements are not the same for off the shelf products.

In this webinar we will discuss some of the factors investigational teams should now consider in planning and executing CGT development programs to include regulatory and logistics issues.

 Join us as we explore:

  • A review of the technologies spanning autologous and allogeneic CAR-Ts, TCRs, iPSCs, TILs and significant expansion of receptor and indication targets
  • Why solid tumors pose additional challenges from an operational perspective
  • How regulatory requirements have modified, and the nuances related to this
  • Manufacturing technology of products is ever more diverse which impinges upon the logistics. Discover some of the solutions to assist in managing the logistics across various technologies

Martin Lachs

VP Project Management Oncology & Cell Therapeutics, ICON

Martin lends operational and indication expertise across a group of over 260 international project management staff globally, dedicated to oncology and cell therapy drug development. He has worked in developing key oncology site networks in the US and the UK and in 2020 was a member of a clinical trial review panel for University of Sydney affiliated hospitals. Martin has produced a number of position papers and presented at numerous international scientific and pharma industry meetings. Recently the key focus of his publications has been thought leadership related to Cell Therapies in oncology, e.g. CAR T.


This program will be beneficial for:

  • Organizations embarking upon the clinical phase of their development programs
  • Staff working on first-in-human (FIH) cell and gene therapies
  • Advanced therapy developers
  • Cell and gene therapy investors
  • Biopharma clinical science professionals